Johnson & Johnson Reports Long-Term Efficacy of Nipocalimab in Myasthenia Gravis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy JNJ?
Source: NASDAQ.COM
- Long-Term Efficacy Data: Johnson & Johnson reports that Nipocalimab maintains disease control for over two years in generalized myasthenia gravis patients, indicating its potential as a durable treatment option that could significantly enhance patient quality of life.
- Clinical Trial Results: In the Phase 3 Vivacity-MG3 study, patients tracked for up to 120 weeks showed consistent improvements in muscle strength and daily living scores, with nearly one-third achieving sustained minimal symptom expression (MSE), highlighting the treatment's effectiveness.
- Side Effects and Safety: More than half of participants reduced corticosteroid use, with no unexpected safety concerns reported; common side effects included muscle spasms and peripheral swelling, demonstrating Nipocalimab's favorable tolerability profile.
- Future Research Directions: Nipocalimab works by blocking the neonatal Fc receptor (FcRn) to lower harmful lgG antibodies, and is being studied in other autoimmune and maternal-fetal conditions, having received multiple regulatory designations including FDA Fast Track and Breakthrough Therapy status.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 226.100
Low
190.00
Averages
218.50
High
240.00
Current: 226.100
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson Reports Long-Term Efficacy of Nipocalimab in Myasthenia Gravis
- Long-Term Efficacy Data: Johnson & Johnson reports that Nipocalimab maintains disease control for over two years in generalized myasthenia gravis patients, indicating its potential as a durable treatment option that could significantly enhance patient quality of life.
- Clinical Trial Results: In the Phase 3 Vivacity-MG3 study, patients tracked for up to 120 weeks showed consistent improvements in muscle strength and daily living scores, with nearly one-third achieving sustained minimal symptom expression (MSE), highlighting the treatment's effectiveness.
- Side Effects and Safety: More than half of participants reduced corticosteroid use, with no unexpected safety concerns reported; common side effects included muscle spasms and peripheral swelling, demonstrating Nipocalimab's favorable tolerability profile.
- Future Research Directions: Nipocalimab works by blocking the neonatal Fc receptor (FcRn) to lower harmful lgG antibodies, and is being studied in other autoimmune and maternal-fetal conditions, having received multiple regulatory designations including FDA Fast Track and Breakthrough Therapy status.
See More
Investors Should Focus on Undervalued Healthcare Stocks
- Market Opportunity Identification: CNBC's Jim Cramer urged investors to look at undervalued sectors, particularly healthcare stocks, which appear more attractive amidst the tech surge, providing diversification for portfolios.
- CVS Health's Market Advantage: Cramer highlighted CVS Health's benefits from a changing competitive landscape, as rivals like Rite Aid disappear and Walgreens scales back, allowing CVS to effectively increase market share through its insurance arm Aetna and numerous retail locations.
- Cardinal Health's Transformation: Cramer noted that Cardinal Health has been unfairly punished without clear reason, yet the company is transitioning from a traditional drug distributor to higher-growth services, particularly in supporting specialty medical practices, showcasing future growth potential.
- Johnson & Johnson's Strong Foundation: Cramer emphasized Johnson & Johnson's robust balance sheet and pipeline of potential blockbuster drugs, coupled with CEO Stephen Hemsley's return, which has bolstered market confidence in its ability to sustain growth.
See More
Investors Should Focus on Undervalued Healthcare Stocks
- Market Opportunity: Jim Cramer highlighted that despite the S&P 500 and Nasdaq hitting new highs, healthcare stocks are undervalued due to solid fundamentals, suggesting investors focus on these overlooked areas for portfolio diversification.
- CVS Health's Competitive Edge: Cramer emphasized that CVS Health is benefiting from a changing competitive landscape, as rivals like Rite Aid disappear and Walgreens scales back, positioning CVS to capture market share with its insurance arm Aetna and extensive retail locations.
- Cardinal Health's Transformation: Cramer noted that Cardinal Health has been unfairly punished without clear reasons, but the company is shifting from its traditional drug distribution role to higher-growth services, particularly in supporting specialty medical practices.
- Johnson & Johnson's Strong Outlook: Cramer pointed out Johnson & Johnson's robust balance sheet and potential blockbuster pipeline, while the return of CEO Stephen Hemsley has stabilized UnitedHealth Group and restored confidence in its growth trajectory.
See More
Johnson & Johnson Shares Set to End Six-Day Losing Streak
- Stock Rebound: Johnson & Johnson (JNJ) shares rose 1.9% to $230.42 on Thursday, breaking a six-day losing streak, despite a cumulative loss of about 5% during that period, indicating market expectations for a short-term recovery.
- Year-to-Date Performance: So far this year, JNJ's stock has increased nearly 10%, significantly outperforming the S&P 500's 4% rise, although it has declined nearly 2% over the past month, reflecting mixed market sentiment regarding its long-term growth potential.
- Analyst Ratings: According to Seeking Alpha's Quant Rating, JNJ holds a score of 3.43 with a Hold rating, receiving an A+ for profitability prospects but a D- for growth factors, highlighting analysts' confidence in its earnings while expressing concerns about growth potential.
- Market Outlook: While Johnson & Johnson is not typically known for mega M&A deals, its diversified portfolio, particularly with double-digit growth in Innovative Medicines and strong performance in MedTech, positions it as “the cleanest growth story in healthcare,” laying a solid foundation for future growth.
See More
Investment Analysis of Small vs. Large Healthcare Stocks
- Small-Cap Potential: CytomX Therapeutics, a clinical-stage company with a market cap of around $1 billion, focuses on cancer treatments and has seen its stock price skyrocket over 625% in the past year; however, it faces risks with no approved drugs and a reported net loss exceeding $20 million in 2025, highlighting the volatility of investing in smaller firms.
- Market Risks: Despite the significant price increase over the past year, CytomX's stock has dropped roughly 40% over the last five years, indicating that investors holding the stock for over four years may be facing losses, which underscores the inherent risks of small-cap healthcare investments.
- Large-Cap Stability: Johnson & Johnson, with a towering market cap of about $545 billion, achieved sales of $88.8 billion in 2024, with projections to grow to between $99.5 billion and $100.5 billion in 2026, showcasing its stable revenue streams and strong market position.
- Consistent Dividends: Johnson & Johnson not only provides stable income but has also increased its dividend for 64 consecutive years; while its sales growth may not match that of small-cap stocks, its stability and profitability make it an ideal choice for investors seeking stability and income.
See More
Investment Comparison: Small vs. Large Healthcare Stocks
- Small-Cap Potential: CytomX Therapeutics, a clinical-stage company with a market cap of around $1 billion, focuses on cancer treatments and has seen its stock price soar over 625% in the past year; however, with no approved drugs and a reported net loss of over $20 million in 2025, it exemplifies the high-risk, high-reward nature of small-cap investments.
- Investment Risks: While CytomX's stock has surged recently, it has dropped approximately 40% over the past five years, highlighting the volatility risks associated with early-stage companies, necessitating careful consideration of holding periods and potential losses by investors.
- Large-Cap Stability: Johnson & Johnson, with a market cap of about $545 billion, achieved sales of $88.8 billion in 2024, projected to rise to between $99.5 billion and $100.5 billion in 2026, showcasing a reliable revenue stream and the ability to consistently pay dividends, having increased its payout for 64 consecutive years.
- Investment Strategy Choice: Choosing between small-cap and large-cap stocks hinges on investors' goals and risk tolerance, with small-caps appealing to those seeking high returns and large-caps better suited for those prioritizing stability and income.
See More
Johnson & Johnson Reports Long-Term Efficacy of Nipocalimab in Myasthenia Gravis
- Long-Term Efficacy Data: Johnson & Johnson reports that Nipocalimab maintains disease control for over two years in generalized myasthenia gravis patients, indicating its potential as a durable treatment option that could significantly enhance patient quality of life.
- Clinical Trial Results: In the Phase 3 Vivacity-MG3 study, patients tracked for up to 120 weeks showed consistent improvements in muscle strength and daily living scores, with nearly one-third achieving sustained minimal symptom expression (MSE), highlighting the treatment's effectiveness.
- Side Effects and Safety: More than half of participants reduced corticosteroid use, with no unexpected safety concerns reported; common side effects included muscle spasms and peripheral swelling, demonstrating Nipocalimab's favorable tolerability profile.
- Future Research Directions: Nipocalimab works by blocking the neonatal Fc receptor (FcRn) to lower harmful lgG antibodies, and is being studied in other autoimmune and maternal-fetal conditions, having received multiple regulatory designations including FDA Fast Track and Breakthrough Therapy status.
See More
Investors Should Focus on Undervalued Healthcare Stocks
- Market Opportunity Identification: CNBC's Jim Cramer urged investors to look at undervalued sectors, particularly healthcare stocks, which appear more attractive amidst the tech surge, providing diversification for portfolios.
- CVS Health's Market Advantage: Cramer highlighted CVS Health's benefits from a changing competitive landscape, as rivals like Rite Aid disappear and Walgreens scales back, allowing CVS to effectively increase market share through its insurance arm Aetna and numerous retail locations.
- Cardinal Health's Transformation: Cramer noted that Cardinal Health has been unfairly punished without clear reason, yet the company is transitioning from a traditional drug distributor to higher-growth services, particularly in supporting specialty medical practices, showcasing future growth potential.
- Johnson & Johnson's Strong Foundation: Cramer emphasized Johnson & Johnson's robust balance sheet and pipeline of potential blockbuster drugs, coupled with CEO Stephen Hemsley's return, which has bolstered market confidence in its ability to sustain growth.
See More
Investors Should Focus on Undervalued Healthcare Stocks
- Market Opportunity: Jim Cramer highlighted that despite the S&P 500 and Nasdaq hitting new highs, healthcare stocks are undervalued due to solid fundamentals, suggesting investors focus on these overlooked areas for portfolio diversification.
- CVS Health's Competitive Edge: Cramer emphasized that CVS Health is benefiting from a changing competitive landscape, as rivals like Rite Aid disappear and Walgreens scales back, positioning CVS to capture market share with its insurance arm Aetna and extensive retail locations.
- Cardinal Health's Transformation: Cramer noted that Cardinal Health has been unfairly punished without clear reasons, but the company is shifting from its traditional drug distribution role to higher-growth services, particularly in supporting specialty medical practices.
- Johnson & Johnson's Strong Outlook: Cramer pointed out Johnson & Johnson's robust balance sheet and potential blockbuster pipeline, while the return of CEO Stephen Hemsley has stabilized UnitedHealth Group and restored confidence in its growth trajectory.
See More
Johnson & Johnson Shares Set to End Six-Day Losing Streak
- Stock Rebound: Johnson & Johnson (JNJ) shares rose 1.9% to $230.42 on Thursday, breaking a six-day losing streak, despite a cumulative loss of about 5% during that period, indicating market expectations for a short-term recovery.
- Year-to-Date Performance: So far this year, JNJ's stock has increased nearly 10%, significantly outperforming the S&P 500's 4% rise, although it has declined nearly 2% over the past month, reflecting mixed market sentiment regarding its long-term growth potential.
- Analyst Ratings: According to Seeking Alpha's Quant Rating, JNJ holds a score of 3.43 with a Hold rating, receiving an A+ for profitability prospects but a D- for growth factors, highlighting analysts' confidence in its earnings while expressing concerns about growth potential.
- Market Outlook: While Johnson & Johnson is not typically known for mega M&A deals, its diversified portfolio, particularly with double-digit growth in Innovative Medicines and strong performance in MedTech, positions it as “the cleanest growth story in healthcare,” laying a solid foundation for future growth.
See More
Investment Analysis of Small vs. Large Healthcare Stocks
- Small-Cap Potential: CytomX Therapeutics, a clinical-stage company with a market cap of around $1 billion, focuses on cancer treatments and has seen its stock price skyrocket over 625% in the past year; however, it faces risks with no approved drugs and a reported net loss exceeding $20 million in 2025, highlighting the volatility of investing in smaller firms.
- Market Risks: Despite the significant price increase over the past year, CytomX's stock has dropped roughly 40% over the last five years, indicating that investors holding the stock for over four years may be facing losses, which underscores the inherent risks of small-cap healthcare investments.
- Large-Cap Stability: Johnson & Johnson, with a towering market cap of about $545 billion, achieved sales of $88.8 billion in 2024, with projections to grow to between $99.5 billion and $100.5 billion in 2026, showcasing its stable revenue streams and strong market position.
- Consistent Dividends: Johnson & Johnson not only provides stable income but has also increased its dividend for 64 consecutive years; while its sales growth may not match that of small-cap stocks, its stability and profitability make it an ideal choice for investors seeking stability and income.
See More
Investment Comparison: Small vs. Large Healthcare Stocks
- Small-Cap Potential: CytomX Therapeutics, a clinical-stage company with a market cap of around $1 billion, focuses on cancer treatments and has seen its stock price soar over 625% in the past year; however, with no approved drugs and a reported net loss of over $20 million in 2025, it exemplifies the high-risk, high-reward nature of small-cap investments.
- Investment Risks: While CytomX's stock has surged recently, it has dropped approximately 40% over the past five years, highlighting the volatility risks associated with early-stage companies, necessitating careful consideration of holding periods and potential losses by investors.
- Large-Cap Stability: Johnson & Johnson, with a market cap of about $545 billion, achieved sales of $88.8 billion in 2024, projected to rise to between $99.5 billion and $100.5 billion in 2026, showcasing a reliable revenue stream and the ability to consistently pay dividends, having increased its payout for 64 consecutive years.
- Investment Strategy Choice: Choosing between small-cap and large-cap stocks hinges on investors' goals and risk tolerance, with small-caps appealing to those seeking high returns and large-caps better suited for those prioritizing stability and income.
See More
